Stoke Therapeutics (STOK) Form 144 Discloses 22,117-Share Sale on NASDAQ
Rhea-AI Filing Summary
Insider proposed sale and recent activity disclosed. This Form 144 notifies the proposed sale of 22,117 common shares of the issuer via Morgan Stanley Smith Barney, with an aggregate market value of $437,253.09 and an approximate sale date of 08/29/2025 on NASDAQ. The filing shows acquisition details: 10,000 shares acquired on 08/29/2025 by exercise of stock options
Positive
- Full disclosure of proposed sale including broker, share count, market value, and planned NASDAQ execution
- Acquisition details provided (option exercise and RSUs) and payment method for the exercised options (cash)
- Recent past sales disclosed for transparency: 13,712 shares on 08/13/2025 and 1,683 shares on 08/18/2025
Negative
- Insider selling activity: proposed sale of 22,117 shares ($437,253.09) and recent August disposals totaling 15,395 shares may be viewed negatively by some investors
- No 10b5-1 plan adoption date provided in the remarks, so reliance on a trading plan is not documented in this filing
Insights
TL;DR Insider proposes to sell 22,117 shares (~$437k) after recent disposals; this is a notable insider liquidity event.
The filing documents a planned sale of 22,117 common shares through Morgan Stanley with an aggregate market value of $437,253.09 and an intended execution on NASDAQ on 08/29/2025. Acquisition records show 10,000 shares from option exercise on 08/29/2025
TL;DR Filing includes standard attestation and broker details; shows prior sales likely executed under trading instructions.
The Form 144 contains broker identification